PMID- 33446490
OWN - NLM
STAT- MEDLINE
DCOM- 20211021
LR  - 20220531
IS  - 2154-1671 (Electronic)
IS  - 2154-1671 (Linking)
VI  - 11
IP  - 2
DP  - 2021 Feb
TI  - Risk Factors for Adverse Events in Children Receiving Outpatient Parenteral 
      Antibiotic Therapy.
PG  - 153-159
LID - 10.1542/hpeds.2020-001388 [doi]
AB  - BACKGROUND: Outpatient parenteral antibiotic therapy (OPAT) can decrease length 
      of hospital stay but is associated with adverse events (AEs). The purpose of this 
      study was to quantify and identify risk factors for OPAT-associated AEs in 
      children. METHODS: Retrospective single-center study of children </=21 years old 
      discharged on OPAT from January 2016 to April 2019 with infectious diseases 
      follow-up. Demographic and clinical factors and medication and central venous 
      catheter (CVC)-associated AEs were assessed through chart review. Univariable and 
      multivariable analyses were performed. RESULTS: Among 181 OPAT courses, an AE 
      occurred in 70 (39%). Medication AEs occurred in 30 of 181 courses (16.6%). 
      Children residing in an urban area had a 4.5 times higher risk of having a 
      medication-related AE compared with those in a rural area (odds ratio: 4.51; 95% 
      confidence interval: 1.60-12.77; P = .005). CVC AEs occurred in 47 of 181 courses 
      (26%). Every additional day of OPAT increased the odds of having a CVC-related AE 
      by 4% (odds ratio: 1.04; 95% confidence interval: 1.01-1.07; P = .003). Twenty 
      (11.1%) courses resulted in readmission to the hospital because of an AE. 
      CONCLUSIONS: In this cohort, 39% of children experienced an OPAT-associated AE, 
      and CVC AEs were more common than medication AEs. Longer duration of intravenous 
      therapy and urban residence were independently associated with OPAT-associated 
      AEs, highlighting the importance of converting to oral antibiotic therapy as soon 
      as feasible to reduce OPAT-associated AEs.
CI  - Copyright (c) 2021 by the American Academy of Pediatrics.
FAU - Townsley, Elizabeth
AU  - Townsley E
AD  - Vanderbilt University Medical Center, Nashville, Tennessee.
FAU - Gillon, Jessica
AU  - Gillon J
AD  - Vanderbilt University Medical Center, Nashville, Tennessee.
FAU - Jimenez-Truque, Natalia
AU  - Jimenez-Truque N
AD  - Vanderbilt University Medical Center, Nashville, Tennessee.
FAU - Katz, Sophie
AU  - Katz S
AD  - Vanderbilt University Medical Center, Nashville, Tennessee.
FAU - Garguilo, Kathryn
AU  - Garguilo K
AD  - Vanderbilt University Medical Center, Nashville, Tennessee.
FAU - Banerjee, Ritu
AU  - Banerjee R
AD  - Vanderbilt University Medical Center, Nashville, Tennessee 
      ritu.banerjee@vumc.org.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210114
PL  - United States
TA  - Hosp Pediatr
JT  - Hospital pediatrics
JID - 101585349
RN  - 0 (Anti-Bacterial Agents)
SB  - IM
MH  - Adolescent
MH  - Anti-Bacterial Agents/adverse effects
MH  - *Central Venous Catheters
MH  - Child
MH  - Child, Preschool
MH  - Humans
MH  - Infant
MH  - *Outpatients
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Young Adult
COIS- POTENTIAL CONFLICT OF INTEREST: Dr Banerjee has received research funding from 
      Accelerate Diagnostics, bioMerieux, Roche, and Biofire. Dr Katz has received 
      research funding from bioMerieux and Roche; the other authors have indicated they 
      have no potential conflicts of interest to disclose.
EDAT- 2021/01/16 06:00
MHDA- 2021/10/27 06:00
CRDT- 2021/01/15 05:46
PHST- 2021/01/16 06:00 [pubmed]
PHST- 2021/10/27 06:00 [medline]
PHST- 2021/01/15 05:46 [entrez]
AID - hpeds.2020-001388 [pii]
AID - 10.1542/hpeds.2020-001388 [doi]
PST - ppublish
SO  - Hosp Pediatr. 2021 Feb;11(2):153-159. doi: 10.1542/hpeds.2020-001388. Epub 2021 
      Jan 14.